Abstract | BACKGROUND: METHODS: Serum samples were collected from 135 PBC patients. Thirty patients with primary sclerosing cholangitis (PSC) and 30 with autoimmune hepatitis (AIH) were included as pathological controls, and 40 healthy blood donors served as healthy controls. The presence of anti-p62 was determined by an in-house ELISA using a recombinant protein. We calculated the sensitivity, specificity, positive and negative predictive values (PPV and NPV), and positive and negative likelihood ratio (LR+ and LR-) of our in-house ELISA for diagnosing PBC based on anti-p62. Findings were correlated with biochemical data and survival. RESULTS: Anti-p62 was detected in 32 PBC patients (23.7%). Specificity and PPV of anti-p62 for PBC were 99% and 97%, respectively. The difference between proportions of anti-p62-positive patients and controls was 0.23 (95% confidence interval [CI]: 0.03-0.40; P<0.0001); LR+ and LR- were 23.7 and 0.77, respectively. The presence of anti-p62 was associated with higher levels of bilirubin and alkaline phosphatase (P<0.001). The odds ratio for survival was 2.44 (95% CI: 0.87-6.87; P=0.091). CONCLUSIONS: Anti-p62 may be regarded as a significant serological marker of PBC.
|
Authors | Alicja Bauer, Andrzej Habior |
Journal | Annals of laboratory medicine
(Ann Lab Med)
Vol. 39
Issue 3
Pg. 291-298
(May 2019)
ISSN: 2234-3814 [Electronic] Korea (South) |
PMID | 30623621
(Publication Type: Journal Article)
|
Copyright | © The Korean Society for Laboratory Medicine. |
Chemical References |
- Autoantibodies
- Membrane Glycoproteins
- Nuclear Pore Complex Proteins
- nuclear pore protein p62
|
Topics |
- Adult
- Aged
- Area Under Curve
- Autoantibodies
(blood)
- Case-Control Studies
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Liver Cirrhosis, Biliary
(diagnosis)
- Male
- Membrane Glycoproteins
(immunology)
- Middle Aged
- Nuclear Pore Complex Proteins
(immunology)
- ROC Curve
- Sensitivity and Specificity
- Young Adult
|